Findings of Scientific Misconduct, 41357-41358 [E8-16357]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 139 / Friday, July 18, 2008 / Notices
can also be submitted by e-mail to
OCAS@CDC.GOV.
can also be submitted by e-mail to
OCAS@CDC.GOV.
Dated: July 2, 2008.
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. E8–16467 Filed 7–17–08; 8:45 am]
Dated: July 2, 2008.
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. E8–16468 Filed 7–17–08; 8:45 am]
BILLING CODE 4163–19–P
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute for Occupational
Safety and Health; Final Effect of
Designation of a Class of Employees
for Addition to the Special Exposure
Cohort
Office of the Secretary
National Institute for
Occupational Safety and Health
(NIOSH), Department of Health and
Human Services (HHS).
ACTION: Notice.
SUMMARY: Notice is hereby given that
the Office of Research Integrity (ORI)
and the Assistant Secretary for Health
have taken final action in the following
case:
J. Keith Hampton, St. Luke’s Hospital:
Based on the report of an investigation
conducted by St. Luke’s Hospital (SLH)
in Chesterfield, MO, and additional
analysis conducted by the Office of
Research Integrity (ORI) during its
oversight review, the U.S. Public Health
Service (PHS) found that J. Keith
Hampton, MSN, APRN, former Clinical
Research Associate, SLH, engaged in
scientific misconduct in research
supported by National Cancer Institute
(NCI), National Institutes of Health
(NIH), awards U10 CA69651, U10
CA12027, and U10 CA33601.
PHS found that Mr. Hampton engaged
in scientific misconduct by falsifying
and fabricating data that were reported
to the National Surgical Adjuvant Breast
& Bowel Project (NSABP) and Cancer
and Leukemia Group B (CALGB)
cooperative research groups.
Specifically, PHS found that:
1. For protocol CALGB 90206,
Respondent:
(a) Falsified a patient’s CT scan
reports and registration forms and
reported the falsified CT scan reports
and registration worksheet to CALGB,
(b) Falsified a patient’s performance
status records (giving 80% performance
status) and registration forms and
reported the falsified performance status
report and registration form to CALGB.
2. For protocol NSABP B–35,
Respondent:
(a) Falsified eligibility data related to
hematology and chemistry assays and to
the performance of a pelvic exam on one
patient’s registration form and reported
the falsified registration forms to the
National Cancer Institute Cancer Trial
Support Unit (CTSU),
(b) Falsified pelvic exam eligibility on
a second patient’s registration form and
AGENCY:
SUMMARY: The Department of Health and
Human Services (HHS) gives notice
concerning the final effect of the HHS
decision to designate a class of
employees at the Nuclear Materials and
Equipment Corporation (NUMEC)
facility in Parks Township,
Pennsylvania, as an addition to the
Special Exposure Cohort (SEC) under
the Energy Employees Occupational
Illness Compensation Program Act of
2000. On May 30, 2008, as provided for
under 42 U.S.C. 7384q(b), the Secretary
of HHS designated the following class of
employees as an addition to the SEC:
dwashington3 on PRODPC61 with NOTICES3
All Atomic Weapons Employer (AWE)
employees who worked at the Nuclear
Materials and Equipment Corporation
(NUMEC) facility in Parks Township,
Pennsylvania, from June 1, 1960, through
December 31, 1980, for a number of work
days aggregating at least 250 work days
occurring either solely under this
employment or in combination with work
days within the parameters established for
one or more other classes of employees in the
Special Exposure Cohort.
This designation became effective on
June 29, 2008, as provided for under 42
U.S.C. 7384l(14)(C). Hence, beginning
on June 29, 2008, members of this class
of employees, defined as reported in
this notice, became members of the
Special Exposure Cohort.
FOR FURTHER INFORMATION CONTACT:
Larry Elliott, Director, Office of
Compensation Analysis and Support,
National Institute for Occupational
Safety and Health (NIOSH), 4676
Columbia Parkway, MS C–46,
Cincinnati, OH 45226, telephone 1–
800–CDC–INFO (1–800–232–4636) or
directly at 1–513–533–6800 (this is not
a toll-free number). Information requests
VerDate Aug<31>2005
15:36 Jul 17, 2008
Jkt 214001
Findings of Scientific Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
41357
reported the falsified registration form
to the CTSU,
(c) Falsified hematology and
chemistry assay eligibility on a third
patient’s registration form and reported
the falsified registration form to the
CTSU.
3. For protocol NSABP B–36,
Respondent falsified a patient’s
multigated acquisition test (MUGA—a
test of heart function) records, cardiac
function, and registration forms,
certified the patient’s eligibility, and
reported the falsified MUGA test,
cardiac function, and registration forms
to the CTSU.
4. For protocol NSABP B–38,
Respondent falsified hematology,
chemistry, and MUGA eligibility for a
patient on the registration form and
reported the falsified registration form
to the CTSU.
5. For protocol NSABP C–08,
Respondent:
(a) Falsified urine protein/creatinine
ratio eligibility for one patient on the
registration form and reported the
falsified registration form to the CTSU,
(b) Falsified urine protein/creatinine
ratio eligibility for a second patient on
the registration form and reported the
falsified registration form to the CTSU,
(c) Falsified claims of the urine
protein/creatinine ratio and PT(INR)
eligibility for a third patient on the
registration form and reported the
falsified registration form to the CTSU.
6. For protocol NSABP R–04,
Respondent falsified a patient’s
colonoscopy report and eligibility at
registration and reported the falsified
colonoscopy report and registration
form to the CTSU.
Mr. Hampton has entered into a
Voluntary Exclusion Agreement
(Agreement) in which he has voluntarily
agreed for a period of three (3) years,
beginning on June 17, 2008:
(1) To exclude himself from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility or involvement in
nonprocurement programs of the United
States Government referred to as
‘‘covered transactions’’ pursuant to
HHS’ Implementation (2 CFR part 376 et
seq.) of OMB Guidelines to Agencies on
Governmentwide Debarment and
Suspension (2 CFR part 180); and
(2) To exclude himself from serving in
any advisory capacity to PHS, including
but not limited to service on any PHS
advisory committee, board, and/or peer
review committee, or as a consultant or
contractor to PHS.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight, Office of Research Integrity,
E:\FR\FM\18JYN1.SGM
18JYN1
41358
Federal Register / Vol. 73, No. 139 / Friday, July 18, 2008 / Notices
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E8–16357 Filed 7–17–08; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors for the
National Center for Public Health
Informatics
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting:
Name: Board of Scientific Counselors for
the National Center for Public Health
Informatics.
Time and Date: 5 p.m.–9 p.m., August 27,
2008.
Place: The Westin Peachtree Plaza, 210
Peachtree Street, Atlanta, Georgia 30303.
Status: Open to the public, limited only by
the space available.
Purpose: The committee shall advise the
Secretary, HHS, and the Director, CDC,
concerning strategies and goals for the
programs and research within the national
centers; shall conduct peer-review of
scientific programs; and monitor the overall
strategic direction and focus of the national
centers. The board, after conducting its
periodic reviews, shall submit a written
description of the results of the review and
its recommendations to the Director, CDC.
The board shall perform second-level peer
review of applications for grants-in-aid for
research and research training activities,
cooperative agreements, and research
contract proposals relating to the broad areas
within the national centers.
Matters To Be Discussed: The agenda will
include an overview of the National Center
for Public Health Informatics (NCPHI),
including its mission, scope and goals.
Detailed discussions will take place on the
following issues: BioSense Strategic
Planning, Open Source Models, and
Organizational Issues for NCPHI.
Agenda items are subject to change as
priorities dictate.
FOR FURTHER INFORMATION CONTACT:
Thomas G. Savel, M.D., Designated Federal
Official, National Center for Public Health
Informatics, CDC, 1600 Clifton Road, NE., MS
E78, Atlanta, Georgia 30333. Telephone 404/
498–2475.
The Director, Management Analysis and
Services office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: July 8, 2008.
Diane Allen,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E8–16449 Filed 7–17–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Safety and Occupational Health Study
Section: Notice of Charter Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the Safety
and Occupational Health Study Section,
Centers for Disease Control and
Prevention, Department of Health and
Human Services, has been renewed for
a 2-year period through June 30, 2010.
For More Information Contact: Price
Connor, PhD, Executive Secretary,
Safety and Occupational Health Study
Section, Department of Health and
Human Services, 1600 Clifton Road,
NE., Mailstop E74, Atlanta, Georgia
30333, telephone 404/498–2511 or fax
404/498–2571.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: July 14, 2008.
Diane Allen,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E8–16450 Filed 7–17–08; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; Comment Request
Proposed Projects
Title: Voluntary Surveys of Program
Partners to Implement Executive Order
12862.
OMB No.: 0980–0266.
Description: Under the provisions of
the Federal Paperwork Reduction Act of
1995 (Pub. L. 104–13), the
Administration for Children and
Families (ACF) is requesting clearance
for instruments to implement Executive
Order 12862 within ACF. The purpose
of the data collection is to obtain
customer satisfaction information from
those entities who are funded to be our
partners in the delivery of services to
the American public. ACF partners are
those entities that receive funding to
deliver services or assistance from ACF
programs. Examples of partners are state
and local governments, territories,
service providers, Indian Tribes and
Tribal organizations, grantees,
researchers, or other intermediaries
serving target populations identified by
and funded directly or indirectly by
ACF. The surveys will obtain
information about how well ACF is
meeting the needs of our partners in
operating the ACF programs.
Respondents: State, Local, & Tribal
Govt. or not-for-profit Organizations
ANNUAL BURDEN ESTIMATES
Number of
respondents
dwashington3 on PRODPC61 with NOTICES3
Instrument
State Governments, Territories and District of Columbia ................................
Head Start Grantees and Delegates ...............................................................
Other Discretionary Grant Programs ...............................................................
Indian Tribes and Tribal Organizations ...........................................................
Estimated Total Annual Burden
Hours: 1,765.
VerDate Aug<31>2005
15:36 Jul 17, 2008
Jkt 214001
54
200
200
25
In compliance with the requirements
of Section 506(c)(2)(A) of the Paperwork
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
10
1
10
10
Average
burden hours
per response
Total burden
hours
1
0.50
0.50
0.50
Reduction Act of 1995, the
Administration for Children and
E:\FR\FM\18JYN1.SGM
18JYN1
540
100
1,000
125
]]>Agencies
[Federal Register Volume 73, Number 139 (Friday, July 18, 2008)]
[Notices]
[Pages 41357-41358]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-16357]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health have taken final action in
the following case:
J. Keith Hampton, St. Luke's Hospital: Based on the report of an
investigation conducted by St. Luke's Hospital (SLH) in Chesterfield,
MO, and additional analysis conducted by the Office of Research
Integrity (ORI) during its oversight review, the U.S. Public Health
Service (PHS) found that J. Keith Hampton, MSN, APRN, former Clinical
Research Associate, SLH, engaged in scientific misconduct in research
supported by National Cancer Institute (NCI), National Institutes of
Health (NIH), awards U10 CA69651, U10 CA12027, and U10 CA33601.
PHS found that Mr. Hampton engaged in scientific misconduct by
falsifying and fabricating data that were reported to the National
Surgical Adjuvant Breast & Bowel Project (NSABP) and Cancer and
Leukemia Group B (CALGB) cooperative research groups.
Specifically, PHS found that:
1. For protocol CALGB 90206, Respondent:
(a) Falsified a patient's CT scan reports and registration forms
and reported the falsified CT scan reports and registration worksheet
to CALGB,
(b) Falsified a patient's performance status records (giving 80%
performance status) and registration forms and reported the falsified
performance status report and registration form to CALGB.
2. For protocol NSABP B-35, Respondent:
(a) Falsified eligibility data related to hematology and chemistry
assays and to the performance of a pelvic exam on one patient's
registration form and reported the falsified registration forms to the
National Cancer Institute Cancer Trial Support Unit (CTSU),
(b) Falsified pelvic exam eligibility on a second patient's
registration form and reported the falsified registration form to the
CTSU,
(c) Falsified hematology and chemistry assay eligibility on a third
patient's registration form and reported the falsified registration
form to the CTSU.
3. For protocol NSABP B-36, Respondent falsified a patient's
multigated acquisition test (MUGA--a test of heart function) records,
cardiac function, and registration forms, certified the patient's
eligibility, and reported the falsified MUGA test, cardiac function,
and registration forms to the CTSU.
4. For protocol NSABP B-38, Respondent falsified hematology,
chemistry, and MUGA eligibility for a patient on the registration form
and reported the falsified registration form to the CTSU.
5. For protocol NSABP C-08, Respondent:
(a) Falsified urine protein/creatinine ratio eligibility for one
patient on the registration form and reported the falsified
registration form to the CTSU,
(b) Falsified urine protein/creatinine ratio eligibility for a
second patient on the registration form and reported the falsified
registration form to the CTSU,
(c) Falsified claims of the urine protein/creatinine ratio and
PT(INR) eligibility for a third patient on the registration form and
reported the falsified registration form to the CTSU.
6. For protocol NSABP R-04, Respondent falsified a patient's
colonoscopy report and eligibility at registration and reported the
falsified colonoscopy report and registration form to the CTSU.
Mr. Hampton has entered into a Voluntary Exclusion Agreement
(Agreement) in which he has voluntarily agreed for a period of three
(3) years, beginning on June 17, 2008:
(1) To exclude himself from any contracting or subcontracting with
any agency of the United States Government and from eligibility or
involvement in nonprocurement programs of the United States Government
referred to as ``covered transactions'' pursuant to HHS' Implementation
(2 CFR part 376 et seq.) of OMB Guidelines to Agencies on
Governmentwide Debarment and Suspension (2 CFR part 180); and
(2) To exclude himself from serving in any advisory capacity to
PHS, including but not limited to service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant or
contractor to PHS.
FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative
Oversight, Office of Research Integrity,
[[Page 41358]]
1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8800.
Chris B. Pascal,
Director, Office of Research Integrity.
[FR Doc. E8-16357 Filed 7-17-08; 8:45 am]
BILLING CODE 4150-31-P
